Centessa Pharmaceuticals Plc (CNTA) - News Archive

In an exciting revelation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024), Centessa Pharmaceuticals unveiled compelling preclinical data for ORX142, a novel Orexin Receptor 2 (OX2R) agoni...

Centessa Pharmaceuticalsn Strategic Movements: A $225M Capital Infusion Amid Promising Clinical AdvancesIn the world of clinical-stage pharma, the balance between financial stability and innovation is precarious. Centes...

Centessa Pharmaceuticals Announces Promising Interim Phase 1 Data for ORX750: A Potential Breakthrough in Treating Sleep Disorders BOSTON and LONDON September 10, 2024 Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clin...

In recent developments at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024), Centessa Pharmaceuticals has made noteworthy strides in the realm of sleep medicine by presenting late-breaking pos...

Centessa Pharmaceuticals Raises $100 Million in Public OfferingCentessa Pharmaceuticals plc, a leading clinical-stage pharmaceutical company focused on groundbreaking treatments for patients, has successfully priced a p...

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines for patients, has recently announced the commencement of an underwritten public offering...

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, recently received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 first-in-human, clinical trial of ORX750. This in...

The biopharmaceutical industry continues to be a locus of innovation and progress, with companies reporting encouraging positive strides which directly impact global healthcare. A pivotal actor in this sector is Centess...